Literature DB >> 16682632

Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers.

Katarina Drakenberg1, Andrej Nikoshkov, Monika Cs Horváth, Pernilla Fagergren, Anna Gharibyan, Kati Saarelainen, Sadia Rahman, Ingrid Nylander, Georgy Bakalkin, Jovan Rajs, Eva Keller, Yasmin L Hurd.   

Abstract

Mu opioid receptors are critical for heroin dependence, and A118G SNP of the mu opioid receptor gene (OPRM1) has been linked with heroin abuse. In our population of European Caucasians (n = 118), approximately 90% of 118G allelic carriers were heroin users. Postmortem brain analyses showed the OPRM1 genotype associated with transcription, translation, and processing of the human striatal opioid neuropeptide system. Whereas down-regulation of preproenkephalin and preprodynorphin genes was evident in all heroin users, the effects were exaggerated in 118G subjects and were most prominent for preproenkephalin in the nucleus accumbens shell. Reduced opioid neuropeptide transcription was accompanied by increased dynorphin and enkephalin peptide concentrations exclusively in 118G heroin subjects, suggesting that the peptide processing is associated with the OPRM1 genotype. Abnormal gene expression related to peptide convertase and ubiquitin/proteosome regulation was also evident in heroin users. Taken together, alterations in opioid neuropeptide systems might underlie enhanced opiate abuse vulnerability apparent in 118G individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682632      PMCID: PMC1472539          DOI: 10.1073/pnas.0600871103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects.

Authors:  J Gelernter; H Kranzler; J Cubells
Journal:  Mol Psychiatry       Date:  1999-09       Impact factor: 15.992

2.  The human HERC family of ubiquitin ligases: novel members, genomic organization, expression profiling, and evolutionary aspects.

Authors:  Karin Hochrainer; Herbert Mayer; Ulrike Baranyi; Berndr Binder; Joachim Lipp; Renate Kroismayr
Journal:  Genomics       Date:  2005-02       Impact factor: 5.736

3.  A comparison between microwave irradiation and decapitation: basal levels of dynorphin and enkephalin and the effect of chronic morphine treatment on dynorphin peptides.

Authors:  I Nylander; C Stenfors; K Tan-No; A A Mathé; L Terenius
Journal:  Neuropeptides       Date:  1997-08       Impact factor: 3.286

4.  The quantification of mortality resulting from the regular use of illicit opiates.

Authors:  G K Hulse; D R English; E Milne; C D Holman
Journal:  Addiction       Date:  1999-02       Impact factor: 6.526

5.  Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum.

Authors:  F Georges; L Stinus; B Bloch; C Le Moine
Journal:  Eur J Neurosci       Date:  1999-02       Impact factor: 3.386

6.  Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden.

Authors:  Gavin Bart; Mary Jeanne Kreek; Jurg Ott; K Steven LaForge; Dmitri Proudnikov; Lotta Pollak; Markus Heilig
Journal:  Neuropsychopharmacology       Date:  2005-02       Impact factor: 7.853

7.  Assignment of the human P532 gene (HERC1) to chromosome 15q22 by fluorescence in situ hybridization.

Authors:  C Cruz; A Paladugu; F Ventura; R Bartrons; C M Aldaz; J L Rosa
Journal:  Cytogenet Cell Genet       Date:  1999

8.  Selective roles for the PC2 processing enzyme in the regulation of peptide neurotransmitter levels in brain and peripheral neuroendocrine tissues of PC2 deficient mice.

Authors:  Ruthellen Miller; Thomas Toneff; Daesety Vishnuvardhan; Margery Beinfeld; Vivian Y H Hook
Journal:  Neuropeptides       Date:  2003-06       Impact factor: 3.286

9.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

10.  Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities.

Authors:  M T Tsuang; M J Lyons; J M Meyer; T Doyle; S A Eisen; J Goldberg; W True; N Lin; R Toomey; L Eaves
Journal:  Arch Gen Psychiatry       Date:  1998-11
View more
  58 in total

1.  No evidence of association between 118A>G OPRM1 polymorphism and heroin dependence in a large Bulgarian case-control sample.

Authors:  Momchil A Nikolov; Olga Beltcheva; Antoaneta Galabova; Anna Ljubenova; Elena Jankova; Galin Gergov; Atanas A Russev; Michael T Lynskey; Elliot C Nelson; Eleonora Nesheva; Dorita Krasteva; Philip Lazarov; Vanio I Mitev; Ivo M Kremensky; Radka P Kaneva; Alexandre A Todorov
Journal:  Drug Alcohol Depend       Date:  2011-01-31       Impact factor: 4.492

2.  Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Authors:  Jermaine D Jones; Rachel R Luba; Jonathan L Vogelman; Sandra D Comer
Journal:  Am J Addict       Date:  2015-12-21

3.  The neural circuitry underlying reinstatement of heroin-seeking behavior in an animal model of relapse.

Authors:  J L Rogers; S Ghee; R E See
Journal:  Neuroscience       Date:  2007-10-22       Impact factor: 3.590

Review 4.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

5.  Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis.

Authors:  Stephen J Glatt; Chad Bousman; Richard S Wang; Kenton K Murthy; Brinda K Rana; Jessica A Lasky-Su; Shao C Zhu; Ruimin Zhang; Jianhua Li; Bo Zhang; Jixiang Li; Michael J Lyons; Stephen V Faraone; Ming T Tsuang
Journal:  Drug Alcohol Depend       Date:  2007-04-09       Impact factor: 4.492

6.  On the role of genetic testing for personalized drug overdose management.

Authors:  Alex Manini; Michelle Jacobs; David Vlahov; Yasmin Hurd
Journal:  J Med Toxicol       Date:  2013-09

Review 7.  Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment.

Authors:  Vadim Yuferov; Orna Levran; Dmitri Proudnikov; David A Nielsen; Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

8.  Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine.

Authors:  Toni-Kim Clarke; Richard C Crist; Kyle M Kampman; Charles A Dackis; Helen M Pettinati; Charles P O'Brien; David W Oslin; Thomas N Ferraro; Falk W Lohoff; Wade H Berrettini
Journal:  Neurosci Lett       Date:  2013-02-20       Impact factor: 3.046

Review 9.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

10.  Progressive Purkinje cell degeneration in tambaleante mutant mice is a consequence of a missense mutation in HERC1 E3 ubiquitin ligase.

Authors:  Tomoji Mashimo; Ouadah Hadjebi; Fabiola Amair-Pinedo; Toshiko Tsurumi; Francina Langa; Tadao Serikawa; Constantino Sotelo; Jean-Louis Guénet; Jose Luis Rosa
Journal:  PLoS Genet       Date:  2009-12-24       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.